Your browser doesn't support javascript.
loading
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.
Shah, Melisa M; Joyce, Brendan; Plumb, Ian D; Sahakian, Sam; Feldstein, Leora R; Barkley, Eric; Paccione, Mason; Deckert, Joseph; Sandmann, Danessa; Hagen, Melissa Briggs; Gerhart, Jacqueline L.
Affiliation
  • Shah MM; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Joyce B; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.
  • Plumb ID; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Sahakian S; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.
  • Feldstein LR; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Barkley E; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.
  • Paccione M; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.
  • Deckert J; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.
  • Sandmann D; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.
  • Hagen MB; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gerhart JL; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.
Clin Infect Dis ; 79(1): 108-110, 2024 Jul 19.
Article in En | MEDLINE | ID: mdl-38411622
ABSTRACT
Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19-.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Ritonavir / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Hospitalization Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Infect Dis Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Ritonavir / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Hospitalization Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Infect Dis Year: 2024 Document type: Article